Trial Condition(s):

Carcinoma, Renal Cell

Nexavar as first targeted therapy in patients with advanced renal cell carcinoma (NEXTAR)

Bayer Identifier:

16091

ClinicalTrials.gov Identifier:

NCT01508364

EudraCT Number:

Not Available

Study Completed

Trial Purpose

This is an observational study which will investigate the use of Nexavar as first targeted therapy in patients with advanced renal cell carcinoma.

Inclusion Criteria
- Patients with a diagnosis of advanced Renal cell carcinoma (RCC) for whom the decision has been taken by the investigator to prescribe Nexavar.
  - Patients who failed cytokine therapy or who are not suitable for cytokines for whom Nexavar is the first targeted drug treatment.
Exclusion Criteria
- Prior targeted therapy for RCC
  - Contraindications of Nexavar described in the Summary of Product Characteristics (SPC).

Trial Summary

Enrollment Goal
20
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Nexavar (Sorafenib, BAY43-9006)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Germany

Status
Completed
 

Trial Design